Receptor Tyrosine Kinases and Their Hormonal Regulation in Uterine Leiomyoma

Linda Yu; Alicia B Moore; Darlene Dixon

doi:10.1055/s-0030-1251482

Seminars in Reproductive Medicine, Inhaltsverzeichnis

Semin Reprod Med 2010; 28(3): 250-259
DOI: 10.1055/s-0030-1251482

Published in 2010 by Thieme Medical Publishers

Receptor Tyrosine Kinases and Their Hormonal Regulation in Uterine Leiomyoma

Linda Yu¹ , Alicia B. Moore¹ , Darlene Dixon¹

¹Cellular and Molecular Pathology Branch (CMPB), National Toxicology Program, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Research Triangle Park, North Carolina

Abstract

ABSTRACT

Uterine leiomyomas (fibroids, myomas) are benign tumors that develop from smooth muscle cells. Although the most common gynecologic tumor in premenopausal women, there is still little known of the etiology, the genetics and basic/molecular biology, or the influence of the environment on the development and growth of these tumors. The fact that fibroids occur during the reproductive years and regress after menopause indicates a growth dependent on ovarian hormones. Studies have supported a role of estrogen and progesterone in leiomyoma growth possibly through regulating growth factors and their signaling pathways. Activation of steroid hormone receptors can have a myriad of effects and include upregulation of growth factors and receptor tyrosine kinases (RTKs), which through downstream effector proteins such as mitogen-activated protein kinase p44/42, can mediate transcription, translation, and cell proliferation. Due to their hormonal dependency, fibroids may also be targeted by environmental chemicals whose biological effects are mediated through the estrogen and/or progesterone receptors. This review focuses on the role of growth factors and their receptors (RTKs) in uterine leiomyoma growth and their regulation by ovarian hormones. It also presents data on specific signaling pathways activated in uterine leiomyomas and the “cross talk” between the estrogen receptor α and RTK signaling pathways.

KEYWORDS

Receptor tyrosine kinases (RTKs) - hormonal regulation - uterus - leiomyoma - growth factors - fibroids

Volltext

Referenzen

REFERENCES

1 Li E, Hristova K. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry. 2006; 45(20) 6241-6251
2 Bennasroune A, Gardin A, Aunis D, Crémel G, Hubert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol. 2004; 50(1) 23-38
3 Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002; 2(10) 795-803
4 Yu L, Saile K, Swartz C D et al.. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med. 2008; 14(5–6) 264-275
5 Wang J, Ohara N, Wang Z et al.. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod. 2006; 21(7) 1869-1877
6 Flake G P, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 2003; 111(8) 1037-1054
7 Shushan A, Ben-Bassat H, Mishani E, Laufer N, Klein B Y, Rojansky N. Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertil Steril. 2007; 87(1) 127-135
8 Mangrulkar R S, Ono M, Ishikawa M, Takashima S, Klagsbrun M, Nowak R A. Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium. Biol Reprod. 1995; 53(3) 636-646
9 Wolańska M, Bańkowski E. Fibroblast growth factors (FGF) in human myometrium and uterine leiomyomas in various stages of tumour growth. Biochimie. 2006; 88(2) 141-146
10 Liang M, Wang H, Zhang Y, Lu S, Wang Z. Expression and functional analysis of platelet-derived growth factor in uterine leiomyomata. Cancer Biol Ther. 2006; 5(1) 28-33
11 Van der Ven L T, Roholl P J, Gloudemans T et al.. Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues. Br J Cancer. 1997; 75(11) 1631-1640
12 Crosier P S, Freeman S A, Orlic D, Bodine D M, Crosier K E. The Dtk receptor tyrosine kinase, which binds protein S, is expressed during hematopoiesis. Exp Hematol. 1996; 24(2) 318-323
13 Motoyoshi K. Function, molecular structure and gene expression of macrophage colony-stimulating factor [in Japanese]. Nippon Rinsho. 1992; 50(8) 1861-1866
14 Pützer B M, Drosten M. The RET proto-oncogene: a potential target for molecular cancer therapy. Trends Mol Med. 2004; 10(7) 351-357
15 Forrester W C. The Ror receptor tyrosine kinase family. Cell Mol Life Sci. 2002; 59(1) 83-96
16 Hoch W. Molecular dissection of neuromuscular junction formation. Trends Neurosci. 2003; 26(7) 335-337
17 Brantley-Sieders D M, Chen J. Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis. 2004; 7(1) 17-28
18 Sun W S, Fujimoto J, Tamaya T. Clinical implications of coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine leiomyoma. Mol Hum Reprod. 2003; 9(11) 701-707
19 Schlessinger J, Lemmon M A. Nuclear signaling by receptor tyrosine kinases: the first robin of spring. Cell. 2006; 127(1) 45-48
20 McKay M M, Morrison D K. Integrating signals from RTKs to ERK/MAPK. Oncogene. 2007; 26(22) 3113-3121
21 Barbarisi A, Petillo O, Di Lieto A et al.. 17-beta estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway. J Cell Physiol. 2001; 186(3) 414-424
22 Levin E R. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol. 2005; 19(8) 1951-1959
23 Mesquita F S, Dyer S N, Heinrich D A et al.. Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. Biol Reprod. 2010; 82(2) 341-351
24 Orcy R B, Brum I, da Silva R S, Kucharski L C, Corleta H E, Capp E. Insulin receptor tyrosine kinase activity and substrate 1 (IRS-1) expression in human myometrium and leiomyoma. Eur J Obstet Gynecol Reprod Biol. 2005; 123(1) 107-110
25 Cook J D, Walker C L. Treatment strategies for uterine leiomyoma: the role of hormonal modulation. Semin Reprod Med. 2004; 22(2) 105-111
26 Sozen I, Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril. 2002; 78(1) 1-12
27 Buttram Jr V C, Reiter R C. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981; 36(4) 433-445
28 Dixon D, Flake G P, Moore A B et al.. Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch. 2002; 441(1) 53-62
29 Lannigan D A. Estrogen receptor phosphorylation. Steroids. 2003; 68(1) 1-9
30 Bunone G, Briand P A, Miksicek R J, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996; 15(9) 2174-2183
31 Hermon T L, Moore A B, Yu L, Kissling G E, Castora F J, Dixon D. Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. Virchows Arch. 2008; 453(6) 557-569
32 Shimomura Y, Matsuo H, Samoto T, Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab. 1998; 83(6) 2192-2198
33 Yamada T, Nakago S, Kurachi O et al.. Progesterone down-regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells. Hum Reprod. 2004; 19(4) 815-821
34 Swartz C D, Afshari C A, Yu L, Hall K E, Dixon D. Estrogen-induced changes in IGF-I, Myb family and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines. Mol Hum Reprod. 2005; 11(6) 441-450
35 Chegini N, Luo X, Ding L, Ripley D. The expression of Smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. Mol Cell Endocrinol. 2003; 209(1-2) 9-16
36 Kato S, Endoh H, Masuhiro Y et al.. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995; 270(5241) 1491-1494
37 Zhao Y, Zhang W, Wang S. The expression of estrogen receptor isoforms alpha, beta and insulin-like growth factor-I in uterine leiomyoma. Gynecol Endocrinol. 2008; 24(10) 549-554
38 Hassan M H, Salama S A, Arafa H M, Hamada F M, Al-Hendy A. Adenovirus-mediated delivery of a dominant-negative estrogen receptor gene in uterine leiomyoma cells abrogates estrogen- and progesterone-regulated gene expression. J Clin Endocrinol Metab. 2007; 92(10) 3949-3957
39 Dixon D, He H, Haseman J K. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect. 2000; 108(Suppl 5) 795-802
40 Di X, Yu L, Moore A B et al.. A low concentration of genistein induces estrogen receptor-alpha and insulin-like growth factor-I receptor interactions and proliferation in uterine leiomyoma cells. Hum Reprod. 2008; 23(8) 1873-1883
41 van der Ven L T, Gloudemans T, Roholl P J et al.. Growth advantage of human leiomyoma cells compared to normal smooth-muscle cells due to enhanced sensitivity toward insulin-like growth factor I. Int J Cancer. 1994; 59(3) 427-434
42 Murphy L J, Ghahary A. Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev. 1990; 11(3) 443-453
43 Adesanya O O, Zhou J, Bondy C A. Sex steroid regulation of insulin-like growth factor system gene expression and proliferation in primate myometrium. J Clin Endocrinol Metab. 1996; 81(5) 1967-1974
44 Giudice L C, Irwin J C, Dsupin B A et al.. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod. 1993; 8(11) 1796-1806
45 Newbold R R. Lessons learned from perinatal exposure to diethylstilbestrol. Toxicol Appl Pharmacol. 2004; 199(2) 142-150
46 Newbold R R, Banks E P, Bullock B, Jefferson W N. Uterine adenocarcinoma in mice treated neonatally with genistein. Cancer Res. 2001; 61(11) 4325-4328
47 Hunter D S, Hodges L C, Eagon P K et al.. Influence of exogenous estrogen receptor ligands on uterine leiomyoma: evidence from an in vitro/in vivo animal model for uterine fibroids. Environ Health Perspect. 2000; 108(suppl 5) 829-834
48 Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet. 1993; 342(8881) 1209-1210
49 Wang T T, Sathyamoorthy N, Phang J M. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis. 1996; 17(2) 271-275

Darlene DixonD.V.M. Ph.D.

Cellular and Molecular Pathology Branch, National Toxicology Program, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services

111 T.W. Alexander Drive, P.O. Box 12233, Bldg. 101/Rm C254A/MD C209, Research Triangle Park, NC 27709

eMail: dixon@niehs.nih.gov